Want to join the conversation?
Matt Sheerin from Stifel asks about the company's thoughts on the M&A front. $TECD said it looks at the three alternatives; namely organic growth, M&A transactions and share repurchases. So over the years the company has had a great allocation in that regard and the company will continue to evaluate those opportunities.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.